LMO2 and leukemia: Despite the great excitement due to successful defective Moloney γRV-based correction of SCID-X1 in children, a major setback was encountered as the therapeutic gene was inserted into the LMO2 proto-oncogene region of the genome leading to leukemia development in a few patients [8,228].